目的:探讨了恶性葡萄胎患者化疗前后血浆leptin、ET-1和血清INH水平变化及临床意义.方法:分别应用放射免疫分析和酶联法对31例恶性葡萄胎患者进行了化疗前后血浆leptin、ET-1和血清INH测定,并与35例正常健康人做比较.结果:恶性葡萄胎患者在化疗前血浆leptin、ET-1和血清INH水平变化均非常显著地高于正常人组(P＜0.01),化疗后6个月与正常人组比较仍有差异(P＜0.05).结论:恶性葡萄胎患者是一种可呈现自身免疫异常和免疫调节障碍的疾病.%Objective To explore the clinical significance of changes of plasma leptin, ET-1 and serum INH levels after chematherapy in patients with malignant hydatidfform mole. Methods Plasma leptin ET-1 ( with RIA ) serum INH ( with ELISA ) levels were measured both before and after chemotherapy in 31 patients with malignant hydatidiform mole as well as in 35 controls. Results Before chemotherapy plasma leptin, ET-1 and serum INH levels were remarkably higher in the patients than those in controls ( P＜ 0.01 ), six months after chemotherapy, the levels changed marked by toward normal, but remained significantly different from those in controls ( P＜ 0.05 ). Conclusion Abnormal autoimmune and immuno-regulation disorder were present in patients with malignant hydatidiform mole.
展开▼
